GSK to buy asth­ma biotech Aio­los Bio for up to $1.4B three months af­ter start­up emerged: #JPM24

SAN FRAN­CIS­CO – GSK will pay $1 bil­lion up­front to buy clin­i­cal-stage asth­ma drug­mak­er Aio­los Bio, the British drug­mak­er said ear­ly Tues­day morn­ing. It could pay up to $400 mil­lion more if mile­stones are met.

The deal marks one of the quick­est start­up un­veil­ing-to-buy­out jour­neys in re­cent biotech mem­o­ry. The San Fran­cis­co and Lon­don biotech emerged just three months ago with one of 2023’s largest pri­vate fi­nanc­ing rounds at $245 mil­lion. At­las Ven­ture, Bain Cap­i­tal Life Sci­ences, For­bion, Sofinno­va In­vest­ments and RA Cap­i­tal Man­age­ment backed the Se­ries A.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER